Reversing course on IPO plans, iTeos draws $125M in private round with crossovers
With one cancer program yielding early data and a second in the clinic, iTeos added crossovers in its series B2
With two programs having entered the clinic since the company’s series B round, iTeos chose to raise another large private round rather than seek to tap the public markets as it had expected, drawing a new $125 million round to fund ongoing development.
The oncology company is calling the new funding a series
